Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21760698 | 0.79 | ALOX12 (0.59) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL21894538 | 0.79 | ALOX12 (0.59) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL12022868 | 0.79 | ALOX12 (0.50) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL13255816 | 0.76 | ALOX12 (0.56) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL13990817 | 0.76 | ALOX12 (0.56) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL10994685 | 0.76 | CYP1A2 (0.70) | ALOX12CYP1A2TDP1MAPK1PKM | |
| SCHEMBL21893409 | 0.76 | ALOX12 (0.56) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL1339860 | 0.76 | CYP1A2 (0.47) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL9607546 | 0.76 | ALOX12 (0.56) | ALOX12CYP1A2TDP1MAPK1ALOX15 | |
| SCHEMBL21893779 | 0.75 | ALOX12 (0.54) | ALOX12CYP1A2TDP1MAPK1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191484-B1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023275336-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-01-05 | — | — | WO | disclosed |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | US | disclosed |
| WO-2022133588-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-30 | — | — | WO | disclosed |
| US-11351178-B2 | Selective HDAC6 inhibitors | ITALFARMACO SPA (IT) | 2022-06-07 | — | — | US | disclosed |
| WO-2020232255-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-11-19 | — | — | WO | disclosed |
| US-10138242-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-20180186789-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2018-07-05 | — | — | US | disclosed |
| US-9840504-B2 | Pyrazolopyridine derivatives and their use in therapy | HELMHOLTZ ZENTRUM MUENCHEN—DEUTSCHES FORSCHUNGZENTRUM FUER GESUNDHEIT UN (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20170247375-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | HELMHOLTZ ZENTRUM MUNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2009020457-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2008139416-A1 | 2-CYCLOPROPYL-THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008117241-A2 | THIAZOLIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008087611-A2 | PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008065626-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVESAS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-05 | — | — | WO | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | ALOX12 1643/4885CYP1A2 980/4885TDP1 4779/4885 |
| US-20220204476-A1 | RNA VIRUS INHIBITOR COMPOUNDS AND USES THEREOF | SARS1, NSUN3, GTF3C4 | ALOX12 1535/4885CYP1A2 4138/4885TDP1 1718/4885 |
| US-20170247375-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | TPP1, PRDX5, TPMT | ALOX12 3981/4885CYP1A2 390/4885TDP1 239/4885 |
| US-20180186789-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | TPP1, PRDX5, TPMT | ALOX12 3981/4885CYP1A2 390/4885TDP1 239/4885 |
| US-10138242-B2 | Pyrazolopyridine derivatives and their use in therapy | TPP1, PRDX5, TPMT | ALOX12 3981/4885CYP1A2 390/4885TDP1 239/4885 |
| US-11351178-B2 | Selective HDAC6 inhibitors | HDAC6, HDAC1, HDAC3 | ALOX12 4491/4885CYP1A2 801/4885TDP1 1612/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | ALOX12 4063/4885CYP1A2 4043/4885TDP1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.